Geron shares drop over 20% after Phase 3 trial termination announcement
FROM THE WIRE · GURUFOCUS.COM
On October 28, 2026, Geron Corporation (NASDAQ: GERN) saw its stock price tumble over 20% following the announcement that its Phase 3 IMpactMF trial for the can
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishA drop this large in a biotech hinges on the trial outcome, relevant for the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Geron shares fell over 20%.
- 02The company announced termination of the Phase 3 IMpactMF trial.
- 03The stock trades on Nasdaq under ticker GERN.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets